Related Experiment Video

Updated: May 13, 2026

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential

T Barbui1, J Thiele, A M Vannucchi

  • 1Department of Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy.

Leukemia
|March 8, 2013
PubMed

Insights

The World Health Organization classification for chronic myeloproliferative neoplasms (MPN) is debated, especially distinguishing essential thrombocythemia (ET) from early primary myelofibrosis (PMF). New research supports early PMF as a distinct entity, necessitating refined diagnostic criteria.

Area of Science:

  • Hematology
  • Oncology
  • Pathology

Background:

  • The World Health Organization (WHO) classification of chronic myeloproliferative neoplasms (MPN) faces challenges in reproducibility and clinical utility.
  • Distinguishing essential thrombocythemia (ET) from early/prefibrotic primary myelofibrosis (PMF) based on histopathology is a key area of controversy.
  • Current WHO guidelines rely on specific bone marrow morphological features and integrated clinical-molecular data for diagnosis.

Purpose of the Study:

  • To address the ongoing debate regarding the diagnostic criteria for MPNs, specifically the distinction between ET and early/prefibrotic PMF.
  • To evaluate the clinical and pathological evidence supporting or refuting early/prefibrotic PMF as a distinct entity.
  • To highlight the need for a collaborative scientific project to establish objective and reproducible diagnostic criteria.

Main Methods:

  • Review and analysis of existing clinico-pathological studies adhering to WHO criteria.
  • Evaluation of histopathological findings in bone marrow morphology.
  • Consideration of molecular-genetic data, such as JAK2V617F mutations, in differential diagnosis.

Main Results:

  • Some studies question the existence of early/prefibrotic PMF, suggesting its inclusion within the ET category.
  • Critiques indicate that certain studies challenging early PMF did not strictly follow WHO diagnostic guidelines.
  • Recent retrospective and prospective studies utilizing WHO criteria provide evidence supporting early/prefibrotic PMF as a distinct clinico-pathologic entity in patients presenting with ET.

Conclusions:

  • The controversy surrounding early/prefibrotic PMF highlights limitations in current diagnostic approaches.
  • Evidence suggests that early/prefibrotic PMF is a distinct entity, necessitating its recognition.
  • A collaborative effort among pathologists and hematologists is crucial to develop robust, objective, and reproducible diagnostic criteria for early/prefibrotic PMF.

More Related Videos

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

Immunophenotyping and Cell Sorting of Human MKs from Human Primary Sources or Differentiated In Vitro from Hematopoietic Progenitors14:30

Immunophenotyping and Cell Sorting of Human MKs from Human Primary Sources or Differentiated In Vitro from Hematopoietic Progenitors

Published on: August 7, 2021

Related Concept Videos

Types of Intermediate Filaments01:31

Types of Intermediate Filaments

The intermediate filaments are an essential component of the cytoskeleton. Presently six types of intermediate filament have been identified. Type I and II are acidic and basic keratin proteins. Type III is of mesodermal origin and comprises four proteins: vimentin, desmin, glial fibrillary acidic protein (GFAP), and peripherin. Vimentin is commonly found in mesenchymal cells, desmin in muscle cells, GFAP in astrocytes, while peripherin is found in peripheral nervous system neurons (PNS). Type...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Pulmonary Embolism I: Introduction01:19

Pulmonary Embolism I: Introduction

A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...